Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Novavax is approved for children aged 12 and older. Both Moderna and Pfizer-BioNTech vaccines use messenger RNA (mRNA), which ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

Pfizer and BioNTech have been among the leaders ... The companies reported mixed results in their phase 3 trial of their mRNA vaccine, which includes antigens for influenza A and B, as well ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of ...